Talaris Therapeutics, Inc. completed its merger with Tourmaline Bio, Inc., resulting in a name change to Tourmaline Bio, Inc. and a reverse stock split. The company also announced changes in control, departure and appointment of directors and officers, and the assumption of existing equity incentive plans.